V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10038377 | 10042591 | 1.77 | 82.8 | null | 2020-01-08 | 2020-01-18 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | null | N | CETUXIMAB | 101256534 |
| 10040757 | 10042592 | 1.85 | 78.5 | Neo-adjuvant (N) | 2015-05-31 | 2015-06-01 | CAPECITABINE + TEMOZOLOMIDE | null | N | OFATUMUMAB | 101688093 |
| 10048165 | 10042594 | 1.52 | 58 | 03 | 2019-11-10 | 2019-11-10 | CYCLOPHOSPHAMIDE + POMALIDOMIDE | 02 | null | FEC + DOCETAXEL + TRASTUZUMAB | 101006788 |
| 10057474 | 10042595 | 1.8 | 70 | null | 2019-02-22 | 2019-03-02 | FCR | 02 | null | BLEOMYCIN + DACARBAZINE + DOXORUBICIN + VINBLASTINE | 100143246 |
| 10057843 | 10042596 | 1.58 | 94 | Curative (C) | 2020-01-01 | 2020-01-07 | RIALTO TRIAL | 02 | N | TRASTUZUMAB | 101687648 |
| 10067832 | 10042598 | 1.7 | 97.7 | Neo-adjuvant (N) | 2021-03-27 | 2021-04-10 | FLUOROURACIL + IRINOTECAN | null | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101493914 |
| 10068099 | 10042599 | 1.76 | 61.5 | Palliative (P) | 2019-01-08 | 2019-01-13 | Apalutamide | 02 | N | CISPLATIN + ETOPOSIDE | 100901461 |
| 10071900 | 10042602 | 1.58 | 76.2 | Palliative (P) | 2019-01-23 | 2019-02-04 | RIALTO TRIAL | 01 | N | DABRAFENIB | 101609848 |
| 10071902 | 10042603 | null | 77.3 | Palliative (P) | 2019-05-12 | 2019-05-14 | CHOP - 21 days | 02 | Y | GEMCITABINE + NAB-PACLITAXEL | 100952302 |
| 10074889 | 10042604 | 1.62 | null | 03 | 2017-06-01 | 2017-06-11 | Apalutamide | N | null | FEC + DOCETAXEL | 101421226 |
| 10078746 | 10042605 | 1.65 | 77 | null | 2020-08-24 | 2020-09-04 | ABVD | 02 | null | SORAFENIB | 100686413 |
| 10088536 | 10042607 | 1.73 | 90 | Neo-adjuvant (N) | 2018-10-15 | 2018-11-01 | Sorafenib | 02 | N | CAPECITABINE + RT | 100846154 |
| 10094200 | 10042609 | null | 94.3 | 03 | 2022-02-27 | 2022-02-27 | Cabazitaxel | null | null | LANREOTIDE | 101308309 |
| 10100529 | 10042611 | 1.55 | 56.5 | 03 | 2021-10-11 | 2021-10-14 | Vemurafenib | null | N | CISPLATIN + PEMETREXED | 101475996 |
| 10104573 | 10042613 | 1.7 | 50.1 | Curative (C) | 2018-10-22 | 2018-10-22 | Bortezomib + Daratumumab | 02 | N | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 100510185 |
| 10115321 | 10042615 | 1.75 | 106.2 | Palliative (P) | 2019-11-01 | 2019-11-05 | AZACITIDINE + VENETOCLAX | 01 | N | GEMCITABINE + NAB-PACLITAXEL | 101842694 |
| 10128575 | 10042618 | 1.68 | 109 | null | 2016-10-09 | 2016-10-19 | CYTARABINE + DAUNORUBICIN + Gemtuzumab Ozogamicin | 02 | null | BRENTUXIMAB | 100141311 |
| 10132630 | 10042619 | 1.77 | 82.8 | Palliative (P) | 2019-03-18 | 2019-03-19 | Cisplatin + Pemetrexed | 02 | N | GDP | 100174718 |
| 10133733 | 10042620 | 1.69 | null | Palliative (P) | 2019-05-08 | 2019-05-08 | R CODOX-M/ R IVAC | 02 | N | GEFITINIB | 101578948 |
| 10137589 | 10042621 | 1.73 | 80.6 | Curative (C) | 2018-01-10 | 2018-01-10 | null | 02 | N | GEMCITABINE + NAB-PACLITAXEL | 100966751 |
| 10137644 | 10042622 | 1.58 | 68.5 | null | 2022-01-23 | 2022-01-29 | Apalutamide | 02 | null | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101386404 |
| 10144014 | 10042624 | 1.81 | 81.9 | Not known (9) | 2020-04-21 | 2020-04-26 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | null | CABAZITAXEL | 100732259 |
| 10144512 | 10042625 | 1.57 | 69.8 | Curative (C) | 2019-08-12 | 2019-08-13 | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN | 02 | null | FEC + DOCETAXEL | 101738502 |
| 10148540 | 10042628 | 0 | null | Palliative (P) | 2022-05-10 | 2022-05-17 | AZACITIDINE + VENETOCLAX | 02 | N | BINIMETINIB + ENCORAFENIB | 101296212 |
| 10153781 | 10042632 | 1.74 | 52.5 | Palliative (P) | 2019-08-01 | 2019-08-08 | Letrozole + Palbociclib | 02 | N | IDELALISIB + RITUXIMAB | 101585619 |
| 10158045 | 10042634 | 1.78 | 86.8 | Palliative (P) | 2022-03-05 | 2022-03-25 | Melphalan oral | 02 | null | CYCLOPHOSPHAMIDE + CYTARABINE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + METHOTREXATE + RITUXIMAB + VINCRISTINE | 100783812 |
| 10161155 | 10042635 | 1.68 | 74 | 03 | 2018-08-09 | 2018-08-19 | Gemcitabine + Oxaliplatin | 02 | null | AML17 TRIAL | 100136510 |
| 10161423 | 10042637 | null | null | Palliative (P) | 2019-05-08 | 2019-05-13 | ABVD | 01 | N | NILOTINIB | 101562909 |
| 10161782 | 10042638 | 1.57 | 87.4 | 03 | 2017-04-23 | 2017-04-23 | Liposomal Doxorubicin 50mg/m2 | 2 | null | CYCLOPHOSPHAMIDE + DOCETAXEL + DOXORUBICIN + PERTUZUMAB + TRASTUZUMAB | 101686103 |
| 10161881 | 10042639 | 1.79 | 73 | Curative (C) | 2017-12-14 | 2018-02-08 | BLEOMYCIN | null | null | LANREOTIDE | 101340558 |
| 10165477 | 10042640 | 1.66 | 88 | 03 | 2022-04-27 | 2022-04-27 | AFATINIB | 02 | N | OSIMERTINIB | 100728062 |
| 10167078 | 10042643 | null | null | Curative (C) | 2017-12-01 | 2017-12-01 | Bevacizumab + CARBOPLATIN + PACLITAXEL | 02 | null | OBINUTUZUMAB + VENETOCLAX | 100442281 |
| 10171102 | 10042644 | 1.65 | 0 | Palliative (P) | 2018-03-05 | 2018-03-08 | REGORAFENIB | 02 | N | CARBOPLATIN + DOCETAXEL | 100051512 |
| 10172420 | 10042646 | 1.81 | 92.8 | Palliative (P) | 2018-06-09 | 2018-06-11 | Ixazomib + Lenalidomide | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + PROCARBAZINE + VINCRISTINE | 101338366 |
| 10172452 | 10042647 | 1.65 | 64 | null | 2016-12-14 | 2016-12-17 | LANREOTIDE | 99 | N | CHLORAMBUCIL + PROCARBAZINE + VINBLASTINE | 100916754 |
| 10175206 | 10042648 | 1.63 | null | Palliative (P) | 2019-10-12 | 2019-10-12 | Ofatumumab Weekly | 02 | N | GEMCARBO | 101115525 |
| 10175292 | 10042650 | 0 | 79 | Palliative (P) | 2018-08-28 | 2018-08-28 | null | 01 | Y | IDELALISIB + RITUXIMAB | 100834633 |
| 10178405 | 10042658 | 0 | null | Curative (C) | 2019-02-05 | 2019-02-28 | Cisplatin+Doxorubicin+Etoposide 28d | 02 | null | ABEMACICLIB + FULVESTRANT | 101422423 |
| 10179413 | 10042661 | 1.93 | 84.7 | null | 2020-01-27 | 2020-02-12 | Liposomal Doxorubicin 50mg/m2 | 02 | null | IDELALISIB + RITUXIMAB | 101002447 |
| 10180673 | 10042664 | 1.64 | 51.4 | Palliative (P) | null | 2017-05-08 | ECX | null | N | VINCRISTINE | 100328458 |
| 10181064 | 10042666 | 1.81 | 70 | Palliative (P) | 2019-08-31 | 2019-08-31 | Irinotecan + Modified De Gramont | 02 | null | APALUTAMIDE | 100920622 |
| 10183838 | 10042668 | 1.57 | 62.7 | Palliative (P) | 2017-10-20 | 2017-11-02 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | 02 | N | ENRICH TRIAL | 100648461 |
| 10183908 | 10042669 | 1.68 | 86.6 | Palliative (P) | 2019-12-15 | 2019-12-15 | Trastuzumab | N | null | FEC | 100408669 |
| 10184123 | 10042670 | null | null | null | null | 2018-10-08 | Capecitabine (14 day) + Irinotecan | null | null | GO2 TRIAL | 100164493 |
| 10184131 | 10042671 | 1.6 | 88.4 | Adjuvant (A) | 2019-07-17 | 2019-07-19 | Oxaliplatin + Modified de Gramont | 02 | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN | 101850665 |
| 10184510 | 10042672 | 1.6 | 63 | Palliative (P) | null | 2018-08-25 | Liposomal Doxorubicin 40mg/m2 | N | N | MELPHALAN | 101551993 |
| 10184522 | 10042673 | 1.65 | 88 | Adjuvant (A) | 2015-12-14 | 2015-12-18 | Bevacizumab | 02 | N | FCR | 100353260 |
| 10184744 | 10042674 | 1.72 | 82 | null | 2019-07-20 | 2019-07-21 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 100040882 |
| 10185049 | 10042676 | 1.6 | 100.6 | Curative (C) | null | 2017-10-20 | ATEZOLIZUMAB + NAB PACLITAXEL | null | null | MATRIX LYMPHOMA TRIAL | 100990781 |
| 10185076 | 10042677 | null | 111.9 | null | 2021-02-06 | 2021-02-23 | FEC 60 or 75 | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100311863 |